IMGN Immunogen Dashboard

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

Company profile

Ticker

IMGN

Exchange

NASDAQ

Website

www.immunogen.com/

CEO

Mark Enyedy

Incorporated

Massachusetts

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

IMMUNOGEN INC

SEC CIK

0000855654

Corporate docs

Articles of Incorporation & Bylaws

IRS number

42726691

IMGN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

ImmunoGen US Patent & Trademark Office Abstract For Co.'s 'SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES'

8 Apr 21

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210101871%22.PGNR.&OS=DN/20210101871&RS=DN/2021

72 Biggest Movers From Yesterday

17 Feb 21

Gainers Socket Mobile, Inc. (NASDAQ: SCKT) shares jumped 538.3% to close at $20.68 on Tuesday, driven by heavy volumes after the company unveiled its DuraSled scanner for iPhone 12s.

64 Biggest Movers From Friday

16 Feb 21

Gainers

12 Health Care Stocks Moving In Friday's Intraday Session

12 Feb 21

Stocks That Hit 52-Week Highs On Friday

12 Feb 21

Press releases

Pro users get this 30m faster

ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

10 Apr 21

First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor Activity in Multiple Solid Tumor Models ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Apr 21

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2021 the compensation committee of the Company's Board of

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Mar 21

ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 26, 2021 the compensation committee of the Company's Board

ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

24 Feb 21

ImmunoGen Reports Recent Progress and 2020 Financial Results

12 Feb 21

Calendar

1 Mar 21

11 Apr 21

31 Dec 21

Financial summary

Financial statements Chart IMGN financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immunogen earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	293.86M	293.86M	293.86M	293.86M	293.86M	293.86M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	(positive/no burn)	1.87M	(positive/no burn)	6.55M
Cash used (since last report)	n/a	n/a	n/a	6.29M	n/a	22.1M
Cash remaining	n/a	n/a	n/a	287.56M	n/a	271.75M
Runway (months of cash)	n/a	n/a	n/a	154.2	n/a	41.5

Beta Read what these cash burn values mean

Recent insider trades

IMGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Mar 21	Mitchell Dean J	Deferred Share Unit Common Stock	Grant	Aquire A	No	No	0	1,666	0	93,774
31 Mar 21	Goldberg Mark Alan	Deferred Share Unit Common Stock	Grant	Aquire A	No	No	0	1,666	0	109,876
5 Feb 21	Renee Lentini	Common Stock Common Stock	Grant	Aquire A	No	No	7.69	80,800	621.35K	80,800
5 Feb 21	Berkenblit Anna	Common Stock Common Stock	Grant	Aquire A	No	No	7.69	282,019	2.17M	282,019
5 Feb 21	Stacy Ann Coen	Common Stock Common Stock	Grant	Aquire A	No	No	7.69	185,016	1.42M	185,016

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

IMGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

86.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	205	183	+12.0%
Opened positions	41	28	+46.4%
Closed positions	19	28	-32.1%
Increased positions	56	47	+19.1%
Reduced positions	72	68	+5.9%

13F shares	Current	Prev Q	Change
Total value	1.12B	510.8M	+118.4%
Total shares	172.9M	141.88M	+21.9%
Total puts	465.8K	135K	+245.0%
Total calls	451.9K	198.4K	+127.8%
Total put/call ratio	1.0	0.7	+51.5%

Largest owners	Shares	Value	Change
Wellington Management	22.08M	$142.44M	-4.3%
Ra Capital Management	18.42M	$118.79M	+161.6%
BLK Blackrock	15.16M	$97.76M	+10.4%
Vanguard	14.16M	$91.31M	-0.2%
FMR	12.54M	$80.9M	+696.8%
Redmile	10.53M	$67.91M	+0.5%
STT State Street	8.8M	$56.79M	-1.8%
Clearbridge Advisors	6.89M	$44.46M	-7.5%
MS Morgan Stanley	4.65M	$29.97M	+158.7%
Renaissance Technologies	4.24M	$27.32M	-34.7%

Largest transactions	Shares	Bought/sold	Change
Ra Capital Management	18.42M	+11.38M	+161.6%
FMR	12.54M	+10.97M	+696.8%
Assenagon Asset Management	0	-4.99M	EXIT
Consonance Capital Management	3.52M	+3.52M	NEW
MS Morgan Stanley	4.65M	+2.85M	+158.7%
Millennium Management	1.95M	-2.8M	-58.9%
Orbimed Advisors	2.55M	+2.55M	NEW
Adage Capital Partners GP, L.L.C.	2.48M	+2.48M	NEW
Renaissance Technologies	4.24M	-2.25M	-34.7%
GS Goldman Sachs	2.62M	+1.69M	+180.5%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Astrazeneca • Seagen • Glaxosmithkline • Stemline Therapeutics • Daiichi Sankyo • Sutro Biopharma • Mersana Therapeutics • Kintara Therapeutics • Xenetic Biosciences

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Academy, accessibility, AgreementSM, Alexion, alter, Altschuller, ample, antileukemia, authoritative, Biden, BIO, Bioverativ, camptothecin, capillary, career, Coen, compendia, CRc, Darden, Enterprise, evergreen, Factoring, folate, graduate, Hangzhou, home, Hong, Huadong, Huntington, interface, intolerance, investor, Kong, leak, linked, LogicBio, Macau, MBA, mortality, NaN, outset, perspective, poster, PR, predetermined, predominantly, prejudice, proportionate, racism, reenacted, relinquishing, Republic, reward, source, Stacy, sublet, Susan, syndrome, synergistic, Taiwan, teen, twenty, Virginia, Viridian, virtual, Wall, weaken, weather, workplace, xenograft, Zhongmei

Removed: affiliate, aggregating, alternatively, anniversary, assured, batch, Bermuda, book, build, cancelled, choice, collectability, commanding, commensurate, compare, comparing, conservative, Cowen, creation, crosslinking, deliverable, discounted, discover, DMx, documented, doxorubicin, element, eligibility, enabling, enhancement, equally, establishment, expensing, feature, finalized, flexibility, forego, foundation, GCC, inauguration, indatuximab, input, invalidated, lab, lieu, liposomal, long, maximum, medium, mid, mitigated, optioned, paclitaxel, pegylated, pembrolizumab, PFS, placement, plant, predicated, preferred, preparing, privately, profit, prompt, ran, reclassed, recognizable, referenced, Reinvestment, reliably, replace, replaced, retrospectively, revaluation, revalue, revert, segregate, shipped, short, SPA, statistical, strong, subset, TCJA, tenant, thereunder, topotecan, triple, unaudited, undelivered, underway, unilateral, unrecognizable, waive, weekly, wide

From filing 10-K 2020 FY